Cardiorenal outcomes in eligible patients referred for bariatric surgery
Objective Bariatric surgery is associated with reduced atherosclerotic cardiovascular disease (CVD) and heart failure hospitalization in people with type 2 diabetes (T2D) and those with prior CVD. Most patients undergoing bariatric surgery do not have T2D or CVD. Many otherwise eligible patients do...
Gespeichert in:
Veröffentlicht in: | Obesity (Silver Spring, Md.) Md.), 2021-12, Vol.29 (12), p.2035-2043 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objective
Bariatric surgery is associated with reduced atherosclerotic cardiovascular disease (CVD) and heart failure hospitalization in people with type 2 diabetes (T2D) and those with prior CVD. Most patients undergoing bariatric surgery do not have T2D or CVD. Many otherwise eligible patients do not have surgery because of self‐exclusion. Clinical outcomes in these groups are less established.
Methods
This study retrospectively assessed cardiorenal outcomes in 8,568 patients after acceptance of referral for surgery.
Results
A total of 63.8% patients did not undergo surgery. After multivariate adjustment for sex, age, BMI, income quintile, distance from hospital, hypertension, T2D, and CVD, hazard ratios (HR) for the primary (incident myocardial infarction, stroke, heart failure hospitalization, and death; HR = 0.52, 95% CI: 0.4‐0.66) and secondary CVD outcomes (primary outcomes and coronary/carotid revascularization; HR = 0.53, 95% CI: 0.42‐0.67) were lower in the surgery cohort. This reduction was seen in those with (primary: HR = 0.45, 95% CI: 0.32‐0.63, secondary: HR = 0.47, 95% CI: 0.34‐0.65) and without T2D (primary: HR = 0.61, 95% CI: 0.42‐0.88, secondary: HR = 0.53, 95% CI: 0.42‐0.67). Reduced kidney disease (HR = 0.46, 95% CI: 0.22‐0.92) but increased liver disease hospitalization (HR = 2.5, 95% CI: 1.45‐4.27) was observed with surgery.
Conclusions
Non‐progression to surgery associates with increased CVD despite low baseline prevalence of CVD. The cardiorenal benefits of bariatric surgery warrant confirmation in a well‐powered randomized clinical trial. |
---|---|
ISSN: | 1930-7381 1930-739X |
DOI: | 10.1002/oby.23294 |